Skip to content
The Policy VaultThe Policy Vault

Rydapt (midostaurin) — Medica

Indolent systemic mastocytosis

Initial criteria

  • age ≥ 18 years
  • symptomatic disease
  • tried at least one systemic regimen (e.g., Ayvakit [avapritinib])

Approval duration

1 year